Drugs /

neomycin

Back to Drugs List

Overview

NCI Definition [1]:
A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.

Clinical Trials

View Clinical Trials for neomycin

Neomycin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating neomycin, 1 is early phase 1 (1 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for neomycin clinical trials.

Colorectal adenocarcinoma and small intestinal adenocarcinoma are the most common diseases being investigated in neomycin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Neomycin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating neomycin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
neomycin so4 pwdr, neomycin so4 pwdr [va product]

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.